

On-line Table 1: The univariate and multivariate logistic analyses for visual impairment before an operation^a

	Baseline VAD						Baseline VFD					
	Absent		Present		Univariate Analysis		Absent		Present		Univariate Analysis	
	n = 33	n = 29	n = 29	n = 29	OR (95% CI)	P Value	n = 11	n = 51	n = 51	n = 51	OR (95% CI)	P Value
Clinical characteristics												
Age	58.5 ± 14.8	50.2 ± 18.4	50.2 ± 18.4	12 (41)	0.97 (0.93–1.01)	.131	64.0 ± 7.9	53.7 ± 17.6	53.7 ± 17.6	53.7 ± 17.6	0.97 (0.93–1.02)	.348
Sex: female	20 (60)	12 (41)	12 (41)		2.18 (0.61–7.81)	.232	7 (64)	27 (51)	27 (51)	27 (51)	1.82 (0.35–9.36)	.474
Duration of symptoms (day)	107.0 ± 158.0	117.0 ± 150.9	117.0 ± 150.9		1.00 (0.98–1.00)	.727	53.5 ± 106.6	124.1 ± 160.3	124.1 ± 160.3	124.1 ± 160.3	1.01 (0.99–1.02)	.374
Imaging evaluation												
Tumor height (mm)	27.0 ± 8.6	35.4 ± 10.1	35.4 ± 10.1		1.10 (1.01–1.19)	.021 ^b	24.6 ± 9.2	32.3 ± 9.9	32.3 ± 9.9	32.3 ± 9.9	1.09 (0.99–1.19)	.076
CC severe	16 (48)	22 (76)	22 (76)		3.34 (0.88–12.72)	.077	3 (27)	36 (71)	36 (71)	36 (71)	10.80 (1.90–61.28)	.007 ^b
Hyperintense ON on T2WI	5 (15)	18 (62)	18 (62)		9.16 (2.41–34.76)	<.001 ^b	2 (18)	21 (41)	21 (41)	21 (41)	3.15 (0.62–15.89)	.165
ONKA	127.4 ± 17.5	102.3 ± 26.8	102.3 ± 26.8		0.95 (0.92–0.98)	<.001 ^b	130.2 ± 17.0	112.5 ± 25.7	112.5 ± 25.7	112.5 ± 25.7	0.96 (0.92–1.00)	.125

Note:—CC indicates chiasmal compression.

^a Data show raw data with percentages in parentheses.

^b $P < .05$.

On-line Table 2: The univariate and multivariate logistic analyses for postoperative improvement of visual impairment^a

	VAD						VFD					
	Good Improvement		Little Improvement		Univariate Analysis		Good Improvement		Little Improvement		Univariate Analysis	
	n = 17	n = 12	n = 12	n = 12	OR (95% CI)	P Value	n = 32	n = 19	n = 19	n = 19	OR (95% CI)	P Value
Clinical characteristics												
Age	52.3 ± 16.5	47.3 ± 21.2	47.3 ± 21.2	8 (66)	0.98 (0.95–1.02)	.347	52.8 ± 19.1	55.2 ± 14.9	55.2 ± 14.9	55.2 ± 14.9	1.01 (0.97–1.05)	.724
Sex: female	9 (53)	8 (66)	8 (66)		1.78 (0.18–4.46)	.457	18 (56)	8 (42)	8 (42)	8 (42)	0.57 (0.12–2.70)	.476
Duration of symptoms (day)	137.2 ± 176.1	87.7 ± 105.3	87.7 ± 105.3		1.00 (0.99–1.00)	.344	133.8 ± 180.9	109.0 ± 124.1	109.0 ± 124.1	109.0 ± 124.1	1.00 (0.99–1.00)	.661
Imaging evaluation												
Tumor height (mm)	36.9 ± 8.9	33.4 ± 11.8	33.4 ± 11.8	9 (75)	0.97 (0.89–1.05)	.388	32.8 ± 9.9	31.3 ± 10.3	31.3 ± 10.3	31.3 ± 10.3	0.98 (0.91–1.07)	.699
CC severe	13 (76)	9 (75)	9 (75)		0.92 (0.12–7.19)	.939	21 (66)	14 (74)	14 (74)	14 (74)	1.27 (0.23–7.19)	.785
Hyperintense ON on T2WI ^c	11 (65)	7 (58)	7 (58)		0.76 (0.19–3.13)	.708	11 (34)	10 (53)	10 (53)	10 (53)	2.12 (0.70–6.44)	.184
ONKA	117.7 ± 18.9	80.5 ± 20.4	80.5 ± 20.4		0.90 (0.82–0.97)	.009 ^b	122.2 ± 17.8	96.2 ± 28.9	96.2 ± 28.9	96.2 ± 28.9	0.95 (0.90–1.00)	.052

^a Data show raw data with percentages in parentheses.

^b $P < .05$.

^c Hyperintense ON on T2WI was not included in multivariate analysis of VAD because of multicollinearity.